NKTR Drug delivery Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company

NKTR 56.31

+0.6%

11:42 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (414)	10/1/2018 11:39:26 AM
From: ghmm	Read Replies (1) of 507

They have a slide presentation and report. I didn't read both just skimming through the slides a couple things: - Not that I am strong in science, but they compare mouse dosing to human dosing when favorable to their argument doesn't seem right. - IL-2 is administered in the ICU and almost no one can get 14 cycles. Yes, NKTR-214 monotherapy was disappointing, however, the premise of it increasing TIL's and providing synergy with other mechanisms has not been disapproved. - Didn't see a price target. NKTR has 2B cash, was a couple Billion before 214 run up AND NKTR-181 hadn't had successful P3 before run-up (which was 1b+).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next